With more than 100 million confirmed COVID-19 cases as of March 2021, reinfection is still
considered to be rare. In light of increasing reports of reinfected COVID-19 patients, the need …

The short-term effectiveness of a two-dose regimen of the BioNTech/Pfizer mRNA BNT162b2
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine was widely …

The duration of protection of the third (booster) dose of the BioNTech/Pfizer BNT162b2
mRNA Coronavirus Disease 2019 vaccine has been the subject of recent investigations, as …

Background Waning of protection against infection with severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) conferred by 2 doses of the BNT162b2 vaccine begins shortly …

Background Reports of waning vaccine-induced immunity against COVID-19 have begun to
surface. With that, the comparable long-term protection conferred by previous infection with …

Objective To examine the relative effectiveness of a fourth dose of the Pfizer-BioNTech
mRNA (BNT162b2) vaccine compared with three vaccine doses over the span of 10 weeks. …

Background: There is insufficient evidence regarding the magnitude and durability of
protection conferred by a combined effect of naturally acquired immunity after SARS-CoV-2 …

Objectives Data regarding women infected with SARS-CoV-2 during early trimesters are
scarce. We aimed to assess preterm birth (PTB) and small-for-gestational-age (SGA) rates in a …

Background Although most children and adolescents have had a previous SARS-CoV-2
infection and many continue to receive COVID-19 vaccinations, studies of the effectiveness of …

Objective Evaluating the prevalence of long-COVID symptoms in patients with a history of
mild or asymptomatic infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-…